France’s ANSM has authorized the Phase I/II HearConnex clinical trial of SENS-601, Sensorion’s investigational AAV-based gene therapy targeting one of the most common causes of genetic congenital deafness, with patient dosing targeted for early 2027....
Continue reading at Hearing Review
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is an early-phase regulatory authorization; no safety or efficacy data are yet available from human trials.
If successful, GJB2-targeted gene therapy could offer a biological hearing restoration option for the most common form of inherited congenital deafness, fundamentally shifting the treatment landscape beyond hearing aids and cochlear implants.
- 01France's ANSM has authorized Sensorion's Phase I/II HearConnex trial of SENS-601.
- 02SENS-601 is an AAV-based (viral vector) gene therapy targeting GJB2 gene mutations — the most common genetic cause of congenital hearing loss.
- 03GJB2 mutations account for a significant proportion of hereditary non-syndromic deafness worldwide.
- 04Patient dosing is planned to begin in early 2027; no human efficacy or safety data exist yet.
- 05This is a Phase I/II trial, meaning the primary focus will be safety and initial dosing, not definitive efficacy.
ANSM (France's national medicines agency) has authorized Sensorion to initiate the HearConnex Phase I/II clinical trial.
press releasesupportedSENS-601 is an AAV-based gene therapy targeting GJB2-related congenital hearing loss.
press releasesupportedPatient dosing under the HearConnex trial is planned for early 2027.
press releasesupported
